Teva Pharmaceutical Indus Analyst Price Targets

Wall Street analyst price targets and consensus rating for Teva Pharmaceutical Indus (TEVA).

Price Target Range — 13 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingBuy# Analysts9Avg. Consensus PT$36Upside to Avg. PT+0.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 4, 2026	UBS	Ashwani Verma	PT Raise	Buy	$42→$48
Aug 12, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$40→$42
Jul 28, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$42→$44
May 6, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$38→$40
Apr 30, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$35→$40
Apr 30, 2026	UBS	Ashwani Verma	PT Raise	Buy	$36→$42
Apr 30, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$41→$42
Apr 30, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$42→$45
Apr 9, 2026	B of A Securities	Jason Gerberry	PT Raise	Buy	$38→$42
Mar 4, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$40→$41
Feb 18, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$38→$42
Feb 9, 2026	Goldman Sachs	Matt Dellatorre	PT Raise	Buy	$36→$45
Jan 30, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$35→$38
Jan 29, 2026	Scotiabank	Louise Chen	PT Raise	Sector Outperform	$35→$40
Jan 29, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$36→$38
Jan 6, 2026	Jefferies	Glen Santangelo	PT Raise	Buy	$29→$40
Dec 22, 2025	Piper Sandler	David Amsellem	PT Raise	Overweight	$30→$40
Dec 19, 2025	Goldman Sachs	Matt Dellatorre	PT Raise	Buy	$31→$35
Dec 16, 2025	JP Morgan	Chris Schott	PT Raise	Overweight	$28→$35
Dec 9, 2025	B of A Securities	Jason Gerberry	PT Raise	Buy	$29→$32

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $42 to $48.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $40 to $42.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44

Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $44.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $38 to $40.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $35 to $40.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $42

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $36 to $42.

Benzinga Newsdesk

Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Indus Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

PRO
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

PRO
JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

PRO
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $42

People Also Watch

People Also Watch

Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Indus Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48

PROBarclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

PROPiper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44

PROBarclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

PROJP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

PROUBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $42

People Also Watch

People Also Watch

PRO
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

PRO
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

PRO
JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

PRO
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $42